BioSpace News Archive

Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented at the Eastern Allergy Conference (EAC).

Reviva Pharmaceuticals Holdings, Inc. announced that it has entered into a definitive agreement for the sale and issuance of 1,898,734 shares of the Company’s common stock and warrants to purchase up to 1,898,734 shares of common stock at a combined offering price of $1.58 per share of common stock and accompanying warrant in a registered direct offering priced at-the-market under the Nasdaq rules.

Imagine Pharma, a biotech company focused on advancing the commercialization of its novel IMG-1 polypeptide in Oral Delivery, Therapeutics, and Regenerative Medicine, announced that the West Virginia University Health System, which operates under the brand WVU Medicine, has awarded a contract to the Company to provide human clinical islet isolation services for patients undergoing a total pancreatectomy and autologous islet cell transplant.

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 11th at 1:30 PM EDT.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony’s management team will participate in a fireside chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL on Monday, June 10, 2024, at 9:20 a.m. ET.

Scholar Rock (NASDAQ: SRRK) today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago.

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced the dosing of the first patient in its Phase 1, first-in-human clinical trial evaluating SOT201, a next-generation PD-1-targeting immunocytokine.

Thermo Fisher Scientific Inc., the world leader in serving science, released its 2023 Corporate Social Responsibility report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.

ASCO Annual Meeting – The Precision Cancer Consortium (PCC), in partnership with Massive Bio, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform.

Clarametyx Biosciences Inc. today announced the appointment of Palani Palaniappan, Ph.D., to its Scientific Advisory Board, as well as the appointments of Stephen Hoffman, M.D., Ph.D. and Paul Westberg, MBA as strategic advisors.